Navigation Links
Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
Date:9/30/2009

CLEVELAND, Sept. 30 /PRNewswire/ -- Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30® (Bacillus coagulans GBI-30, 6086), today announced two grants for early investigators. Grants focus on researching the effects of GanedenBC30 on human immune cells. Previous studies have demonstrated the ability of GanedenBC30 to modulate numerous human immune cells, both in vitro and in vivo.

To be eligible, investigators must have a full-time faculty appointment at a research institution or medical school. Applicants must have interest in studying the effects of GanedenBC30 on human immune cells, as well as the capacity to conduct such research.

Two grants will be funded at a maximum of $15,000 for each project. Applicants will be expected to submit a budget outlining how the funds will be used. A meeting with Ganeden's Scientific Board will be required prior to the start of the research, as well as following the research to present the results. Travel for these meetings will be subsidized above the grant amount.

Applications will be reviewed by:

  • Ken Alibek, CEO, AFG Bioscience
  • John Endres, chief scientific officer, AIBMR Life Sciences
  • Sean Farmer, chief scientific officer, Ganeden Biotech
  • Glenn Gibson, professor, University of Reading
  • Gary Huffnagle, professor, University of Michigan
  • David Keller, vice president of scientific operations, Ganeden Biotech

Grant applications will be judged on quality of the proposed experimental design, originality of the proposal, evidence of the applicant's ability to conduct the proposed research, and relevance of the proposed research to the health of the general population.

Please contact Dr. David Keller at keller@ganedenbiotech.com for all requests and submission of applications. The deadline for applications is December 31, 2009.

"Ganeden Biotech is happy to announce these grants to early investigators," said Ganeden Biotech CSO and co-founder Sean Farmer. "We believe that research is core to the probiotics industry, and that these grants will enable early investigators to add to the current body of research demonstrating the health benefits of probiotics."

About Ganeden Biotech

Founded in 1996, Ganeden Biotech Inc. is a private company based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage and Sustenex brands. It also licenses its patented probiotic bacteria, GanedenBC30, for use in commercial food and beverage applications as well as in medical foods and dietary supplements. GanedenBC30 was found to be Generally Recognized As Safe (GRAS) by an independent expert panel assembled to assess its safety in use as a food ingredient. Digestive Advantage and Sustenex are available at over 40,000 retailers nationwide including Wal-Mart, CVS/pharmacy, Walgreens, Rite-Aid, Stop & Shop, Giant, Publix, Kroger, and Target. For more information, visit www.digestiveadvantage.com, www.sustenex.com, or www.ganedenlabs.com.

SOURCE Ganeden Biotech Inc.


'/>"/>
SOURCE Ganeden Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
3. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
4. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
6. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
7. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
8. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
9. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
10. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
11. Researchers at Axial Biotech Develop a DNA Test for Scoliosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... Florida , January 19, 2017 ... Trump administration appears serious about reducing the FDA,s ... and innovation in the medical drug industry, many ... ahead with new clinical trials and development of ... companies forging ahead with recent developments include:  Moleculin ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate ... the electrifying line-up of events for its annual meeting “Coming Home 2017,” an ... “Coming Home 2017” will be held on Friday January 27 through Sunday, ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
(Date:1/20/2017)... ... 2017 , ... Source Vitál Apothecary, a skin and body care company dedicated ... company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition ... in the nutritional, sports and health industries a chance to meet in private sessions ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... ... and wellness products to enhance people’s everyday lives, recently attended the January ECRM ... buyers. , ATP Science is known for its large range of supplements that ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched ... The drinks have been produced in collaboration with Zlatan Ibrahimovic and have been ... , After a successful launch in Sweden last year, the next generation sports ...
Breaking Medicine News(10 mins):